BenevolentAI Logo

BenevolentAI

Applies artificial intelligence to accelerate drug discovery and development.

BAI | AS

Overview

Corporate Details

ISIN(s):
LU2355630455
LEI:
2221003P54KEDC3P4Z33
Country:
United Kingdom
Address:
4-8 Maple Street, W1T 5HD London

Description

BenevolentAI is a clinical-stage company that specializes in applying artificial intelligence (AI) and machine learning to drug discovery and development. The company utilizes its proprietary technology platform, which is built upon a comprehensive knowledge graph, to analyze vast amounts of complex biomedical information. This platform is designed to generate novel biological insights, identify new therapeutic targets, and accelerate the research and development process for new medicines. By integrating advanced AI with scientific expertise, BenevolentAI aims to decipher complex disease biology and improve the efficiency and success rate of bringing new treatments to patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-03-21 11:00
benevolentai-2022-12-31-en
English 13.0 MB
2023-03-21 11:00
Annual Report 2022 published - 21 March 23 - FINAL
English 94.5 KB
2023-03-16 07:00
BAI FY22 Results FINAL APPROVED
English 562.4 KB
2023-01-13 16:01
Notification of major holdings - P.Schoenfeld Asset Management LP
English 64.7 KB
2022-09-27 14:55
BAI Analyst and Investor Event Disclosure 27 Sept 22 FINAL
English 110.7 KB
2022-09-27 07:00
BenevolentAI H1 22 - Interim Results FINAL APPROVED
English 366.8 KB
2022-08-24 13:38
220824 PDMR Notifications
English 81.8 KB
2022-06-30 16:56
BenevolentAI - Press Release AGM Results FINAL FINAL
English 99.3 KB
2022-05-30 07:28
BenevolentAI - Convening Notice 2022 AGM [As Published in RESA 30052022]
English 89.0 KB
2022-05-25 08:35
Board Changes FINAL
English 143.0 KB
2022-04-28 15:42
PDMR Notification (Dr. Ann Jacqueline Hunter) - April 2022
English 336.8 KB
2022-04-27 14:40
BenevolentAI - Press Release (Treasury Shares) [As Published 27042022]
English 95.0 KB
2022-04-26 18:39
BenevolentAI Notification - Total number of voting rights and capital 26042022
English 132.3 KB
2022-04-22 14:28
Alchemy - Press Release (Completion of Business Combination)
English 119.6 KB
2022-04-11 18:49
Odyssey Acquisition S.A. EGM 11 April 2022 - Press Release
English 136.2 KB

Automate Your Workflow. Get a real-time feed of all BenevolentAI filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BenevolentAI

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BenevolentAI via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.